ADAR1 Capital Management LLC Sells 15,900 Shares of Insmed, Inc. $INSM

by · The Cerbat Gem

ADAR1 Capital Management LLC lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 72.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,074 shares of the biopharmaceutical company’s stock after selling 15,900 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Insmed were worth $463,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky purchased a new stake in Insmed during the 1st quarter valued at approximately $975,000. OneDigital Investment Advisors LLC boosted its position in shares of Insmed by 47.1% during the first quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company’s stock worth $399,000 after acquiring an additional 1,673 shares during the last quarter. Sowell Financial Services LLC purchased a new position in Insmed during the first quarter valued at $255,000. GAMMA Investing LLC increased its holdings in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 386 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Insmed by 16.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 541 shares during the last quarter.

Analysts Set New Price Targets

INSM has been the subject of several research reports. Jefferies Financial Group increased their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Citigroup raised Insmed to a “buy” rating in a research note on Tuesday, June 10th. Royal Bank Of Canada raised their price target on Insmed from $108.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Mizuho upped their price objective on Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. Finally, HC Wainwright increased their target price on Insmed from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, June 11th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average target price of $132.57.

View Our Latest Analysis on Insmed

Insider Activity at Insmed

In other news, COO Roger Adsett sold 25,000 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company’s stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider owned 89,407 shares of the company’s stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 515,927 shares of company stock valued at $51,447,211 over the last three months. Corporate insiders own 3.00% of the company’s stock.

Insmed Trading Up 0.8%

Shares of NASDAQ INSM opened at $136.10 on Tuesday. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $136.90. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business’s 50 day moving average is $111.35 and its two-hundred day moving average is $88.01. The stock has a market capitalization of $28.77 billion, a P/E ratio of -23.84 and a beta of 0.96.

Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

(Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Further Reading